Pursuant to N.J.S.A. 45:1-45 et. seq., pharmacies that dispense Schedule II-V Controlled Dangerous Substances (CDS) in New Jersey, or into New Jersey, are required to submit data on all transactions for such drugs to the New Jersey Prescription Monitoring Program (NJPMP).
The New Jersey Division of Consumer Affairs, using its discretion under the NJPMP statute, added the requirement that pharmacies provide data on all transactions related to Human Growth Hormone (HGH).
Pharmacies must upload the required CDS and HGH prescription data via www.NJRxReport.com.
Pharmacies must submit this data at least twice per month. They are encouraged to report prior to the deadlines, to allow for the correction of any rejected submissions. Pharmacies may report more frequently if they prefer to do so.
For technical assistance with the NJPMP database, contact Optimum Technology’s help desk at 1-866-683-2476 or njrxreport@otech.com.
Important Links:
- NJPMP Data Collection Manual.
- On July 21, 2011, the Division of Consumer Affairs hosted a web meeting in order to demonstrate the NJPMP data submission process for the benefit of pharmacy permit and registration holders, and their software vendors. Click for instructions on viewing the July, 21 2011 PMP Demonstration Meeting.
- Letter to Pharmacy Permit and Registration Holders, sent July 7, 2011.
- Exemption/Waiver Application. Note: An Application for Waiver or Exemption must be signed by the applicant using an electronic or handwritten signature. The Division of Consumer Affairs will not process any application submitted without the applicant’s signature.
